Kite, Novartis update CAR T timelines at ASH

Kite Pharma Inc. (NASDAQ:KITE) and Novartis AG (NYSE:NVS; SIX:NOVN) each provided updates on their lead chimeric antigen receptor (CAR) T cell therapies targeting CD19. Updates for both programs, which are nearing FDA review, occurred at the American Society of Hematology (ASH) meeting in San Diego.

Kite said it began submitting a

Read the full 506 word article

User Sign In